MedTrace Logo

Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

NCT00402532 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2011-12-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether Everolimus is effective in the treatment and prevention of chronic graft dysfunction and chronic graft rejection after lung transplantation.

Conditions

  • Lung Transplantation

Interventions

DRUG

Everolimus

Initial dosage 2 x 0.75 mg/d

DRUG

Mycophenolatmofetil

Initial dosage 2 x 500 mg/d intravenous

Sponsors & Collaborators

Principal Investigators

  • Martin Strueber, Dr. · Hannover Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402532 on ClinicalTrials.gov